(RTTNews) - Sarepta Therapeutics, Inc. (SRPT) Monday reported positive topline results from Part 2 of the Phase 3 study, dubbed EMBARK, of its gene therapy Elevidys approved for the treatment of ...
While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback